Benefits
Supports the body's own nitric oxide production
S7's polyphenols are studied for helping the body make more of its own nitric oxide rather than supplying nitrates. In a 90-day trial, circulating stable NO (measured as nitrosylated hemoglobin) rose more in the S7 groups than placebo, supporting healthy NO status.
Promotes healthy blood flow and circulation
Nitric oxide acts as a vasodilator, signaling blood vessels to relax. By supporting NO availability, S7 is intended to promote healthy circulation and the exercise 'pump' many athletes seek, without stimulants or added nitrates.
Antioxidant support against everyday free radicals
The seven botanicals are rich in polyphenols and anthocyanins with antioxidant activity. In the human study, S7 was associated with lower mitochondrial reactive oxygen species generation, suggesting it helps the body manage oxidative stress.
Non-stimulant option for active adults
Because it works at a low milligram dose and is designed to boost endogenous NO, S7 offers a caffeine-free, non-nitrate way to support workout blood flow, making it suitable for stacking into pre-workouts or stimulant-free formulas.
Mechanism of action
Upregulation of endogenous nitric oxide
Dietary polyphenols from the seven botanicals are thought to enhance the body's own NO output (via nitric oxide synthase pathways and preserved NO bioavailability) rather than acting as an exogenous nitrate donor. The trial tracked NO as nitrosylated hemoglobin (NOHb), a stable circulating reservoir.
Reduction of mitochondrial reactive oxygen species
Excess ROS scavenge and degrade NO. By lowering mitochondrial ROS generation, S7's antioxidant polyphenols may preserve NO from oxidative breakdown, indirectly increasing the amount of bioavailable nitric oxide.
Polyphenol and anthocyanin antioxidant activity
Green tea catechins, chlorogenic acids from green coffee, curcuminoids from turmeric, and anthocyanins from tart cherry and blueberry contribute overlapping free-radical-quenching and redox-signaling effects that underpin the blend's antioxidant profile.
Clinical trials
Randomized, double-blind, placebo-controlled study of S7 itself (Nemzer et al., 2021, Journal of Food Research 10(2):21). Note: this journal is not PubMed-indexed and several authors are affiliated with the manufacturer, so it has not been externally corroborated.
42 overweight or slightly obese adults assigned to placebo, 25 mg S7, or 50 mg S7 once daily for 90 days.
Circulating stable NO (NOHb) increased about 34% (25 mg) and 53% (50 mg) versus a small placebo rise, while mitochondrial ROS generation fell about 54% and 75% versus a slight placebo increase. Results are from a single small trial and should be viewed as preliminary.
Small double-blind, placebo-controlled crossover pilot reported by the manufacturer (FutureCeuticals); this is a manufacturer/unpublished pilot, not an independently indexed publication.
8 healthy adults aged 24–55 given a single 50 mg dose of S7 versus placebo.
A single 50 mg dose was associated with roughly a 230% increase in circulating nitric oxide. This is a very small, short pilot and the figure is widely quoted in marketing; it should be interpreted cautiously.
Human studies on SPECTRA, a separate FutureCeuticals polyphenol blend, NOT the finished S7 product (Nemzer et al., 2014, Food Science & Nutrition; Nemzer et al., 2018, Free Radical Research). Included only as mechanistic support for the botanical-polyphenol NO/antioxidant class.
Healthy adults in placebo-controlled designs measuring reactive oxygen/nitrogen species and NO markers.
The SPECTRA blend significantly lowered cellular and mitochondrial ROS and influenced NO/nitrosative markers, supporting the general concept that low-dose polyphenol blends can modulate oxidative stress and NO — but these data are on a different product, not S7.